Scarica l'app Stockscreener
6.03
0.00%
0.00
Dopo l'orario di chiusura:
6.03
Precedente Chiudi:
$6.03
Aprire:
$5.86
Volume 24 ore:
444.93K
Relative Volume:
0.68
Capitalizzazione di mercato:
$572.13M
Reddito:
-
Utile/perdita netta:
$-68.65M
Rapporto P/E:
-5.0596
EPS:
-1.1918
Flusso di cassa netto:
$-64.93M
1 W Prestazione:
-0.17%
1M Prestazione:
-10.80%
6M Prestazione:
+47.07%
1 anno Prestazione:
+415.38%
Intervallo 1D:
$5.77
$6.10
Intervallo di 1 settimana:
$5.595
$6.45
Portata 52W:
$0.97
$7.44
Zura Bio Ltd Stock (ZURA) Company Profile
Nome
Zura Bio Ltd
Settore
Industria
Telefono
858-247-0520
Indirizzo
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
6.03 | 572.13M | 0 | -68.65M | -64.93M | -1.1918 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-09 | Iniziato | Wedbush | Outperform |
| 2024-11-04 | Iniziato | Leerink Partners | Outperform |
| 2024-09-05 | Iniziato | H.C. Wainwright | Neutral |
| 2024-05-03 | Iniziato | Piper Sandler | Overweight |
| 2023-10-10 | Iniziato | Ladenburg Thalmann | Buy |
| 2023-08-25 | Iniziato | Oppenheimer | Outperform |
| 2023-06-22 | Iniziato | Guggenheim | Buy |
| 2023-06-14 | Iniziato | Chardan Capital Markets | Buy |
| 2023-05-24 | Iniziato | Raymond James | Strong Buy |
Mostra tutto
Zura Bio Ltd Borsa (ZURA) Ultime notizie
Biotechnology executive pays $15 million for Pinecrest home - The Business Journals
Zura Bio (ZURA) CTO awarded 263,000 share options at $6.03 strike price - Stock Titan
Zura Bio (ZURA) officer receives 340,900 options at $6.03 strike price - Stock Titan
Zura Bio (ZURA) CFO receives stock options for 340,900 shares at $6.03 - Stock Titan
Zura Bio grants 425,700 options to legal chief | ZURA Insider Trading - Stock Titan
Zura Bio (ZURA) CEO awarded options on 894,000 Class A shares - Stock Titan
Chipmakers Recap: Is Zura Bio Limited a momentum stock2026 Highlights & Verified Swing Trading Watchlist - baoquankhu1.vn
Market Fear: Will Zura Bio Limited benefit from rising consumer demandChart Signals & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Zura Bio (NASDAQ:ZURA) Price Target Raised to $11.00 at Chardan Capital - Defense World
Zura Bio Ltd reports results for the quarter ended December 31Earnings Summary - tradingview.com
ZURA: Chardan Capital Maintains 'Buy' Rating and Raises Price Ta - gurufocus.com
Oppenheimer Lowers Zura Bio (NASDAQ:ZURA) Price Target to $15.00 - Defense World
ZURA: Oppenheimer Lowers Price Target, Maintains Outperform Rati - GuruFocus
Zura Bio (NASDAQ:ZURA) Given New $15.00 Price Target at Oppenheimer - MarketBeat
Zura Bio Ltd expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Zura Bio Ltd Aktie surges on positive Phase 2 data for autoimmune drug candidate - AD HOC NEWS
Zura Bio Limited 2025 Annual Report: Clinical-Stage Biotech Advancing Novel Autoimmune Therapies and Key Risk Factors - Minichart
Zura Bio (NASDAQ: ZURA) outlines autoimmune pipeline, Phase 2 timelines - Stock Titan
Zura Bio GAAP EPS of -$1.06 misses by $0.31 - One News Page
Zura Bio 10-K: $0.0M Revenue, $(X.XX) EPS on reported net loss - TradingView
2025 financial update released as Zura Bio outlines new corporate developments - Traders Union
Zura Bio (NASDAQ: ZURA) raises cash to fund Phase 2 trials - Stock Titan
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates - ChartMill
Ajay Nirula Net Worth (2026) - GuruFocus
Jessica Chen - White & Case LLP
Boothbay Fund Management LLC Acquires New Shares in Zura Bio Limited $ZURA - MarketBeat
Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 16.2% in February - MarketBeat
Zura Bio Limited $ZURA Stock Holdings Boosted by Suvretta Capital Management LLC - MarketBeat
ZURA Technical Analysis & Stock Price Forecast - Intellectia AI
Atika Capital Management LLC Takes Position in Zura Bio Limited $ZURA - Defense World
Zura Bio’s Tibulizumab: First-in-Class Bispecific Antibody Targeting IL-17 and BAFF for Autoimmune Diseases (HS & SSc) – Pipeline, Trials, and Market Opportunity 2348 - Minichart
Zura Bio Updates Corporate Outlook on Lead Tibulizumab Program - TipRanks
Zura Bio updates corporate presentation, flags tibulizumab Phase 2 readouts, cash and shares - TradingView
Updated investor presentation furnished by Zura Bio (NASDAQ: ZURA) - Stock Titan
ZURA Stock Price, Quote & Chart | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
Zura Bio presents Phase 2 systemic sclerosis trial design By Investing.com - Investing.com Australia
Zura Bio presents Phase 2 systemic sclerosis trial design - Investing.com South Africa
Zura Bio launches Phase 2 TibuSURE trial in systemic sclerosis at Athens congress - Traders Union
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress - weeklyvoice.com
Director at Zura Bio (ZURA) awarded 37,812 share options - Stock Titan
Major Zura Bio (ZURA) holder acquires 2M shares in registered deal - Stock Titan
Access Industries group lifts Zura Bio (ZURA) stake to 18.2% - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Zura Bio heads to Miami for March 10-11 investor conferences - Stock Titan
Zura Bio raises $144 million in public offering of shares By Investing.com - Investing.com South Africa
Zura Bio raises $144 million in public offering of shares - Investing.com India
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - ChartMill
Zura Bio (ZURA) revises Ogier legal opinion and consent in 8-K/A - Stock Titan
Zura Bio prices $125M public offering at $6.25 per share - Investing.com Australia
Zura Bio (ZURA) launches $6.25 share and pre-funded warrant sale - Stock Titan
Zura Bio Ltd Azioni (ZURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):